Monoprost (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, enhancing uveoscleral outflow of aqueous humor. This increased drainage reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Monoprost is determined by the prescribing ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact dose and timing must follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Monoprost, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often have a more favorable dosing schedule but may cause distinct ocular side effects such as iris pigmentation.

Monoprost should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep it out of reach of children.

Monoprost is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the prescribed eye(s) without touching the tip of the bottle to the eye.

Serious risks include severe allergic reactions, uveitis, corneal edema, and a paradoxical rise in intra‑ocular pressure. Patients should seek immediate medical attention if they experience significant eye pain, vision changes, or signs of an allergic response.

Monoprost is contraindicated in patients with active ocular inflammation such as uveitis, known hypersensitivity to latanoprost or any component of the formulation, and should be used with caution in pregnant or nursing women unless clearly indicated by a physician.